- Home »
- Quarterly Results »
- Akums Drugs & Pharmaceuticals Q1 Results Revenue Rises to ₹10,191.13 Million with Net Profit of ₹612.08 Million
Akums Drugs & Pharmaceuticals Q1 Results Revenue Rises to ₹10,191.13 Million with Net Profit of ₹612.08 Million
Akums Drugs & Pharmaceuticals Q1 Results show a 7.9% QoQ revenue increase to ₹10,191.13 million, and Akums Drugs & Pharmaceuticals Q1 Results reveal a net profit of ₹612.08 million, up from the previous quarter’s loss.
by P Nandhini
Updated Aug 26, 2024
Table of Content
Akums Drugs & Pharmaceuticals Q1 Results: Akums Drugs & Pharmaceuticals announced their Q1 results on 24th August 2024, showcasing a mixed performance for the quarter. The company reported a revenue of ₹10,191.13 million, reflecting a quarter-over-quarter (QoQ) growth of 7.9% from ₹9,442.09 million in the previous quarter.
However, when compared year-over-year (YoY), the revenue showed a modest increase of 5.1% from ₹9,698.86 million in Q1 of the previous year. Despite the increase in revenue, Akums faced challenges in profitability.
The profit before tax (PBT) for Q1 stood at ₹874.78 million, a significant improvement from a loss of ₹328.83 million in the previous quarter, but still showing a decline compared to the profit of ₹1,587.93 million recorded in Q1 of the previous year.
The company’s net profit for the quarter was ₹612.08 million, reversing the loss of ₹394.68 million from the previous quarter, but falling short of the previous year’s Q1 profit.
For More Q1 results check our Twitter Page
Akums Drugs & Pharmaceuticals Q1 Results 2024 - 2025
Akums Drugs & Pharmaceuticals has released its financial results for the first quarter of the 2024-2025 fiscal year. The company showed a steady increase in revenue compared to the previous quarter, although profits remained under pressure. Below is a summary of the key financial metrics for Q1 2024-2025:
| Particulars | Q1 2024-2025 | Q4 2023-2024 | Q1 2023-2024 |
|---|---|---|---|
| Revenue from Operations (₹ million) | 10,191.13 | 9,442.09 | 9,698.86 |
| Other Income (₹ million) | 65.46 | 102.41 | 80.94 |
| Total Income (₹ million) | 10,256.59 | 9,544.50 | 9,779.80 |
| Cost of Materials Consumed (₹ million) | 5,594.96 | 5,132.99 | 5,448.47 |
| Employee Benefits Expense (₹ million) | 1,762.23 | 1,639.54 | 1,565.59 |
| Finance Costs (₹ million) | 130.21 | 123.77 | 121.49 |
| Depreciation and Amortisation Expense (₹ million) | 340.64 | 339.53 | 297.17 |
| Profit Before Tax (PBT) (₹ million) | 874.78 | (328.83) | 1,587.93 |
| Net Profit (₹ million) | 612.08 | (394.68) | 1,874.27 |
| Earnings Per Share (EPS) (₹) | 4.21 | (2.89) | 13.16 |
| Total Comprehensive Income (₹ million) | 618.37 | (390.89) | (1,877.53) |
Source: Here
Akums Drugs & Pharmaceuticals Current Market Overview
Akums Drugs & Pharmaceuticals is currently trading at ₹927 per share, showing a slight decline of 1.48%. The company has a significant market capitalization of ₹14,586 crore, highlighting its strong position in the pharmaceutical industry.
Over the past year, the stock has fluctuated between a high of ₹1,176 and a low of ₹724. Despite its size, Akums has a low Return on Capital Employed (ROCE) of 2.40% and a negative Return on Equity (ROE) of -3.57%.
The company does not currently offer any dividend yield, and its stock has a face value of ₹2.00.
| Parameter | Details |
|---|---|
| Current Price | ₹927 |
| Price Change | -1.48% |
| Market Cap | ₹14,586 Cr. |
| 52-Week High | ₹1,176 |
| 52-Week Low | ₹724 |
| ROCE | 2.40% |
| ROE | -3.57% |
| Dividend Yield | 0.00% |
| Face Value | ₹2.00 |
| BSE Code | 544222 |
| NSE Code | AKUMS |
Quarterly Results
Here are the quarterly financial results for Akums Drugs & Pharmaceuticals for June 2023, March 2024, and June 2024. The data shows a significant improvement in various financial metrics over the periods.
| Parameter | Jun 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|
| Sales (₹ in crore) | 970 | 944 | 1,019 |
| Expenses (₹ in crore) | 1,095 | 941 | 891 |
| Operating Profit (₹ in crore) | -125 | 3 | 128 |
| Operating Profit Margin (OPM %) | -13% | 0% | 13% |
| Other Income (₹ in crore) | 8 | 10 | 7 |
| Interest (₹ in crore) | 12 | 12 | 13 |
| Depreciation (₹ in crore) | 30 | 34 | 34 |
| Profit Before Tax (₹ in crore) | -159 | -33 | 87 |
| Tax % | 18% | 20% | 30% |
| Net Profit (₹ in crore) | -187 | -39 | 61 |
| Earnings Per Share (EPS in Rs) | -13.16 | -2.89 | 4.08 |
About Akums Drugs & Pharmaceuticals
Akums Drugs & Pharmaceuticals is India's largest contract development and manufacturing organization (CDMO), and it is known for its leading role in the domestic pharmaceutical market. Established in 2004, the company operates 15 advanced manufacturing facilities that produce a wide range of modern medicines across various therapeutic areas.
Akums offers comprehensive services, including formulation development, clinical trials, and securing approvals for new drug combinations. With a strong focus on innovation and quality, Akums has received over 200 awards, making it a trusted partner for many pharmaceutical companies in India and beyond.
Visit our website for more Q1 results.
Akums Drugs & Pharmaceuticals Q1 Results - FAQs
1. What is the revenue reported by Akums Drugs & Pharmaceuticals for Q1 2024-2025?
The revenue for Q1 2024-2025 is ₹10,191.13 million.
2. What was the net profit of Akums Drugs & Pharmaceuticals for Q1 2024-2025?
The net profit for Q1 2024-2025 was ₹612.08 million.
3. How did Akums Drugs & Pharmaceuticals' revenue for Q1 2024-2025 compare to the previous quarter?
Revenue increased from ₹9,442.09 million in the previous quarter to ₹10,191.13 million.
4. What was Akums Drugs & Pharmaceuticals' profit before tax (PBT) for Q1 2024-2025?
The PBT for Q1 2024-2025 was ₹874.78 million.
5. Did Akums Drugs & Pharmaceuticals show a profit or loss in the previous quarter?
The previous quarter showed a loss of ₹328.83 million.
6. What was the earnings per share (EPS) for Akums Drugs & Pharmaceuticals in Q1 2024-2025?
The EPS for Q1 2024-2025 was ₹4.21.
7. How did the net profit for Q1 2024-2025 of Akums Drugs & Pharmaceuticals compare to Q1 2023-2024?
The net profit for Q1 2024-2025 was ₹612.08 million, compared to ₹1,874.27 million in Q1 2023-2024.
8. What was the total income reported by Akums Drugs & Pharmaceuticals for Q1 2024-2025?
The total income for Q1 2024-2025 was ₹10,256.59 million.
9. What was the total comprehensive income for Akums Drugs & Pharmaceuticals in Q1 2024-2025?
The total comprehensive income was ₹618.37 million.